National Research (NASDAQ:NRC) Raised to “Buy” at Wall Street Zen
by Mitch Edgeman · The Markets DailyNational Research (NASDAQ:NRC – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.
NRC has been the subject of several other reports. Weiss Ratings upgraded shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Citizens Jmp increased their price target on shares of National Research from $26.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 28th. Finally, Zacks Research upgraded shares of National Research to a “hold” rating in a report on Monday, October 5th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $27.00.
Check Out Our Latest Analysis on National Research
National Research Stock Performance
Shares of NASDAQ NRC opened at $25.86 on Friday. National Research has a 12 month low of $11.73 and a 12 month high of $27.41. The company has a market cap of $588.32 million, a P/E ratio of 92.36 and a beta of 0.22. The business’s 50 day moving average is $21.55 and its two-hundred day moving average is $19.30. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 13.13.
National Research (NASDAQ:NRC – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.03. The company had revenue of $38.40 million during the quarter, compared to analysts’ expectations of $35.80 million. National Research had a return on equity of 313.25% and a net margin of 4.48%. On average, equities analysts expect that National Research will post 0.97 EPS for the current year.
Institutional Trading of National Research
Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in National Research by 872.7% during the third quarter. Russell Investments Group Ltd. now owns 39,756 shares of the company’s stock worth $842,000 after buying an additional 35,669 shares in the last quarter. Simplex Trading LLC raised its stake in shares of National Research by 556.4% in the 3rd quarter. Simplex Trading LLC now owns 3,282 shares of the company’s stock valued at $70,000 after buying an additional 2,782 shares in the last quarter. Integrity Alliance LLC. acquired a new position in shares of National Research in the 3rd quarter valued at $538,000. Farmers & Merchants Investments Inc. lifted its holdings in shares of National Research by 51.7% during the 3rd quarter. Farmers & Merchants Investments Inc. now owns 501,731 shares of the company’s stock worth $10,632,000 after acquiring an additional 171,082 shares during the period. Finally, Empirical Finance LLC bought a new position in shares of National Research during the 2nd quarter worth about $431,000. Institutional investors and hedge funds own 47.26% of the company’s stock.
National Research Company Profile
National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.
Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.